1. Pharmacological strategies to lower crosstalk between nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondria
- Author
-
Jie Yang, Ge Lv, Nirmala Koju, Abdoh Taleb, Qilong Ding, Xian Cao, Jifang Zhou, and Hui Lei
- Subjects
0301 basic medicine ,Antioxidant ,ROS induced ROS release (RIRR) ,medicine.medical_treatment ,RM1-950 ,Mitochondrion ,medicine.disease_cause ,Antioxidants ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Animals ,Humans ,Endothelial dysfunction ,Pharmacology ,chemistry.chemical_classification ,Reactive oxygen species ,NADPH oxidase ,biology ,NADPH Oxidases ,General Medicine ,medicine.disease ,Mitochondria ,Cell biology ,Oxidative Stress ,Crosstalk (biology) ,030104 developmental biology ,Antioxidant defense system ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Therapeutics. Pharmacology ,Reactive Oxygen Species ,Nicotinamide adenine dinucleotide phosphate ,Oxidative stress - Abstract
Reactive oxygen species (ROS) are the metabolites of oxygen that plays a significant role in cell signaling and homeostasis. Under normal conditions, ROS formation is stabilized by various antioxidant defense systems (ROS scavengers). Several studies in both in-vitro and in-vivo models, together with clinical data indicated that increased production ROS and oxidative stress plays a crucial role in the development and progression of endothelial dysfunction. The interactions between the main cellular sources of ROS, such as mitochondria and NADPH oxidases, however, remain unclear. The purpose of this review is to outline various sources of ROS and describe the crosstalk between NADPH oxidase and mitochondria. Further, we will discuss different antioxidants that lower ROS production and ROS-induced pathological conditions such as aging, atherosclerosis, diabetes, hypertension, and degenerative neurological disorders. In this review, we have mainly focused on antioxidants that inhibit NADPH oxidase and mitochondrial sources of ROS. Moreover, the modification of antioxidants (targeted therapy) may be a significant approach for management of oxidative stress induced pathophysiological complications.
- Published
- 2019
- Full Text
- View/download PDF